Movantik (naloxegol), an oral peripherally acting mu-opioid receptor antagonist, has been approved by the FDA for the treatment of opioid-induced constipation in adults with chronic non-cancer pain.
New guidelines have been issued in relation to the management of irritable bowel syndrome and chronic idiopathic constipation. The updated guidelines were published as a supplement to the August issue of the American Journal of Gastroenterology.
Abuse-deterrent properties, identical efficacy for pain relief, reversal of opioid-induced constipation, and theoretical tolerance mitigation may give Targiniq ER an interesting advantage over other oral opioids.
One of the most common treatment courses for chronic pain is comprised of prescription opioid medications. However, concerns about drug addiction and abuse oftentimes outweigh the drugs’ pain-relieving benefits.
Treatment with the oral, peripherally acting µ-opioid receptor antagonist naloxegol is safe and effective for opioid-induced constipation, according to a study published online June 4 in the New England Journal of Medicine.
Patients with IBS-D in two phase II trials of eluxadoline experienced sustained improvements in abdominal pain and bowel symptoms at 26 weeks of treatment, with mild side effects.